MA26751A1 - Procede pour la preparation d'inhibiteurs de 5- lipoxygenase ayant divers systemes cycliques heterocycliques - Google Patents

Procede pour la preparation d'inhibiteurs de 5- lipoxygenase ayant divers systemes cycliques heterocycliques

Info

Publication number
MA26751A1
MA26751A1 MA26054A MA26054A MA26751A1 MA 26751 A1 MA26751 A1 MA 26751A1 MA 26054 A MA26054 A MA 26054A MA 26054 A MA26054 A MA 26054A MA 26751 A1 MA26751 A1 MA 26751A1
Authority
MA
Morocco
Prior art keywords
preparation
lipoxygenase inhibitors
various heterocyclic
cyclic systems
heterocyclic cyclic
Prior art date
Application number
MA26054A
Other languages
English (en)
Inventor
Francis Lambert John
Elizabeth Hnatow Megan
Norris Timothy
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26751A1 publication Critical patent/MA26751A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 31/08/1999 60/151,615 "Procédé pour la préparation d'inhibiteurs de 5-lipoxygénase ayant divers systèmes cycliques hétérocycliques" L'invention concerne un intermédiaire de procédé nouveau consistant en le tétrahydro-4-[3-(4-fluorophényl)thio]phényl-2H-pyranne-4-carboxamide de formule Elle concerne également un procédé pour sa préparation. Application : utilisation de cet intermédiaire dans un procédé pour la préparation d'inhibiteurs de 5-lipoxygénase.
MA26054A 1999-08-31 2000-08-30 Procede pour la preparation d'inhibiteurs de 5- lipoxygenase ayant divers systemes cycliques heterocycliques MA26751A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15161599P 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
MA26751A1 true MA26751A1 (fr) 2004-12-20

Family

ID=22539529

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26054A MA26751A1 (fr) 1999-08-31 2000-08-30 Procede pour la preparation d'inhibiteurs de 5- lipoxygenase ayant divers systemes cycliques heterocycliques

Country Status (33)

Country Link
US (1) US6346624B1 (fr)
EP (1) EP1081143A1 (fr)
JP (1) JP2001106682A (fr)
KR (1) KR20010050256A (fr)
CN (1) CN1286250A (fr)
AP (1) AP2000001910A0 (fr)
AU (1) AU5360300A (fr)
BG (1) BG104731A (fr)
BR (1) BR0003945A (fr)
CA (1) CA2317097A1 (fr)
CZ (1) CZ20003158A3 (fr)
EA (1) EA200000801A1 (fr)
EE (1) EE200000512A (fr)
GT (1) GT200000142A (fr)
HR (1) HRP20000564A2 (fr)
HU (1) HUP0003439A3 (fr)
ID (1) ID27129A (fr)
IL (1) IL138087A0 (fr)
IS (1) IS5603A (fr)
MA (1) MA26751A1 (fr)
NO (1) NO20004313L (fr)
NZ (1) NZ506632A (fr)
OA (1) OA11452A (fr)
PA (1) PA8499701A1 (fr)
PE (1) PE20010520A1 (fr)
PL (1) PL342281A1 (fr)
SG (1) SG87146A1 (fr)
SK (1) SK12872000A3 (fr)
SV (1) SV2002000159A (fr)
TN (1) TNSN00177A1 (fr)
TR (1) TR200002529A2 (fr)
UY (1) UY26314A1 (fr)
ZA (1) ZA200004435B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6669042B1 (en) * 2002-09-30 2003-12-30 Hewlett-Packard Development Company, L.P. Integrated positioning and locking device
US7674811B2 (en) 2006-03-14 2010-03-09 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883106A (en) * 1994-10-18 1999-03-16 Pfizer Inc. 5-lipoxygenase inhibitors
US6063928A (en) * 1994-10-18 2000-05-16 Pfizer Inc 5-lipoxygenase inhibitors
SK281577B6 (sk) 1994-10-18 2001-05-10 Pfizer Inc. Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze
US6239285B1 (en) * 1998-02-06 2001-05-29 Pfizer Inc Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems

Also Published As

Publication number Publication date
PE20010520A1 (es) 2001-04-28
NO20004313L (no) 2001-03-01
HUP0003439A2 (hu) 2001-08-28
HUP0003439A3 (en) 2002-08-28
TR200002529A2 (tr) 2001-04-20
EE200000512A (et) 2001-04-16
CA2317097A1 (fr) 2001-02-28
NZ506632A (en) 2002-02-01
ZA200004435B (en) 2002-02-28
BG104731A (en) 2001-09-28
IS5603A (is) 2001-03-01
NO20004313D0 (no) 2000-08-30
HRP20000564A2 (en) 2001-12-31
HU0003439D0 (en) 2000-08-30
SG87146A1 (en) 2002-03-19
ID27129A (id) 2001-03-01
JP2001106682A (ja) 2001-04-17
IL138087A0 (en) 2001-10-31
SK12872000A3 (sk) 2001-11-06
UY26314A1 (es) 2001-04-30
GT200000142A (es) 2002-02-19
BR0003945A (pt) 2001-04-03
PL342281A1 (en) 2001-03-12
PA8499701A1 (es) 2001-12-14
EP1081143A1 (fr) 2001-03-07
EA200000801A1 (ru) 2001-04-23
US6346624B1 (en) 2002-02-12
KR20010050256A (ko) 2001-06-15
CN1286250A (zh) 2001-03-07
TNSN00177A1 (fr) 2005-11-10
SV2002000159A (es) 2002-01-23
CZ20003158A3 (cs) 2001-09-12
OA11452A (en) 2003-12-08
AU5360300A (en) 2001-03-08
AP2000001910A0 (en) 2000-09-30

Similar Documents

Publication Publication Date Title
ES2134847T3 (es) Derivados de taxol.
BR0109703A (pt) Derivados de piperazina
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
AU5722800A (en) Imidazoline derivatives for the treatment of diabetes, especially type ii diabetes
DK1159279T3 (da) 4-Oxo-4,7-dihydro-thieno[2,3-b]pyridin-5-carboxamider som antivirale midler
MX9605741A (es) Clorhidrato cristalino del (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzisotiazol-2-il)-butil ]-aminometil} cromano.
WO2005021497A3 (fr) Trimeres et dimeres fixes de 1,4-diphenylazetidin-2-ones
WO2001064645A3 (fr) Derives de quinoline utilises comme antagonistes alpha2
DE60026404D1 (de) Verfahren zur Herstellung von Benzothiophen-Derivaten
AU2003300911A1 (en) Heterocyclic compounds as ccr5 antagonists
DE69008142D1 (de) 4-Substituierten Imidazolen zur Senkung des intraokularen Druckes.
WO2000059285A3 (fr) Nouveaux inhibiteurs de lactame de metalloproteases matricielles, de tnf-alpha, et de l'aggrecanase
SI1274685T1 (sl) Derivat piridin-1-oksida in postopek njegove transformacije v farmacevtsko ucinkovite sestavine
AU5727899A (en) Diaminocyclobutene-3,4-dione derivatives, their preparation and use
PT1204658E (pt) Agonistas benzofurilpiperazina de serotonina
MA26751A1 (fr) Procede pour la preparation d'inhibiteurs de 5- lipoxygenase ayant divers systemes cycliques heterocycliques
HUT70196A (en) New 2-[4-(4-azolyl-butyl)-1-piperazinyl] derivatives, process for producing them and their use in pharmaceutical compositions
WO2004056832A3 (fr) Derives d'epothilone
CA2432138A1 (fr) Nouvelle methode de synthese de l'eletriptan
IL112630A (en) Derivatives of (2-(ar)alkyldithioindane-2-carboxamido) tricyclic-oxobenzazepine and similar compouds useful as inhibitors of enkephalinase, their preparation and pharmaceutical compositions containing them
WO2004078115A3 (fr) Composes de benzothiazole, compositions et procedes pour le traitement et la prophylaxie des infections par rotavirus et des maladies associees
MXPA05008331A (es) Derivados de 3-(benzoilureido)-tiofeno sustituido, metodo para su produccion y uso de los mismos.
GB0309440D0 (en) Quinolone derivatives
CA2443012A1 (fr) Utilisation de derives de pyridoindolone pour la preparation de medicaments
DE60006125D1 (de) Herstellung von 2-(2-arylmorpholin-2-yl)ethanolderivaten und zwischenprodukte